Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sim, V.
Right arrow Articles by Penney, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sim, V.
Right arrow Articles by Penney, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Family Practice Vol. 20, No. 5, 570-574
© Oxford University Press 2003

Health Services Research

The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction— cost-effectiveness in relation to open access echocardiography

Victor Sim, David Hamptona, Ceri Phillipsb, Su-Neng Loc, Sanjeev Vasishtac, John Daviesc and Micheal Penneya

Department of Medicine, Llandough Hospital, Vale of Glamorgan,
a Department of Clinical Biochemistry and
c Department of Cardiology, Royal Gwent Hospital, Newport and
b Centre for Health Economics and Policy Studies, School of Health Science, University of Wales Swansea, Singleton Park, Swansea, UK.

Correspondence to Dr Victor Sim, Directorate of Medicine, On Call Landing, Llandough Hospital, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX, UK; E-mail: victor.sim{at}uhw-tr.wales.nhs.uk

Background. Heart failure due to left ventricular systolic dysfunction (LVSD) has a high prevalence in the adult population but is difficult to diagnose accurately on clinical grounds in the community. Early diagnosis is important as effective treatments are available to reduce morbidity and mortality. Echocardiography is widely used to assess heart failure; however, this technology is relatively expensive and of limited availability. A potential diagnostic aid in primary care is the measurement of plasma brain natriuretic peptide (BNP).

Objective. This study was performed to assess the value of BNP measurement as a selective pre-screen for breathless patients referred for open access echocardiography.

Methods. BNP was measured by radioimmunoassay with prior extraction in 83 breathless subjects (age range 37–87 years, mean 72). Standard echocardiography was performed and left ventricular systolic function was assessed.

Results. The prevalence of LVSD was 31% in this group. At cut-off values chosen to give negative predictive values for LVSD of >98% (BNP = 19 pg/ml), the sensitivity, specificity and positive predictive value for BNP were 100, 49.1 and 46.9%. Using this BNP threshold as a pre-screen for echocardiography would make a net saving of £964.20 without compromising the diagnostic accuracy.

Conclusion. BNP measurement appears to have a significant cost-effective benefit for the selection of patients for echocardiography.

Keywords. Brain natriuretic peptide, cost-effectiveness, echocardiography, heart failure, open access.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.